Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Incidence of Pneumocystis jiroveci Pneumonia among Groups at Risk in HIV-negative Patients.
[waldenström macroglobulinemia]
Pneumocystis
jiroveci
pneumonia
in
HIV-negative
immunocompromised
patients
is
associated
with
high
mortality
rates
.
Although
trimethoprim-sulfamethoxazole
(
TMP-SMX
)
provides
a
very
effective
prophylaxis
,
pneumocystosis
still
occurs
and
may
even
be
emerging
,
due
to
sub-optimal
characterization
of
patients
most
at
risk
,
hence
precluding
targeted
prophylaxis
.
We
retrospectively
analyzed
all
cases
of
documented
pneumocystosis
in
HIV-negative
patients
admitted
in
our
institution
,
a
referral
center
in
the
area
,
from
January
1990
to
June
2010
,
and
extracted
data
on
their
underlying
condition
(
s
)
.
To
estimate
incidence
rates
within
each
condition
,
we
estimated
the
number
of
patients
followed-up
in
our
area
for
each
condition
,
by
measuring
the
number
of
patients
admitted
with
the
corresponding
international
classification
diagnostic
code
,
through
the
national
hospital
discharge
database
(
PMSI
)
.
From
1990
to
2010
,
293
cases
of
pneumocystosis
were
documented
,
of
whom
154
(
52
.
6
%
)
tested
negative
for
HIV
.
The
main
underlying
conditions
were
hematological
malignancies
(
32
.
5
%
)
,
solid
tumors
(
18
.
2
%
)
,
inflammatory
diseases
(
14
.
9
%
)
,
solid
organ
transplant
(
12
.
3
%
)
,
and
vasculitis
(
9
.
7
%
)
.
Estimated
incidence
rates
could
be
ranked
in
three
categories
:
i
)
high
risk
(
incidence
rates
>
45
cases
per
100
,
000
patient-
year
)
:
polyarteritis
nodosa
,
granulomatosis
with
polyangiitis
,
polymyositis
/
dermatopolymyositis
,
acute
leukemia
,
chronic
lymphocytic
leukemia
,
and
non-
Hodgkin
lymphoma
;
ii
)
intermediate
risk
(
25
-
45
cases
per
100
,
000
patient-
year
)
:
Waldenström
macroglobulinemia
,
multiple
myeloma
,
and
central
nervous
system
cancer
;
and
iii
)
low
risk
(
<
25
cases
per
100
,
000
patient-
year
)
:
other
solid
tumors
,
inflammatory
diseases
,
and
Hodgkin
lymphoma
.
These
estimates
may
be
used
as
a
guide
to
better
target
pneumocystosis
prophylaxis
in
the
groups
most
at
risk
.
Diseases
Validation
Diseases presenting
"multiple myeloma"
symptom
erdheim-chester disease
esophageal adenocarcinoma
familial mediterranean fever
severe combined immunodeficiency
systemic capillary leak syndrome
waldenström macroglobulinemia
wolf-hirschhorn syndrome
This symptom has already been validated